FRANKFURT, 7 September (Reuters) – Biotechnology company BioNTech said Monday that it had expanded an ongoing global pivot in its COVID-19 candidate vaccine to include evidence in its home country, Germany.
The German vaccine regulator, the Paul Ehrlich Institute, approved the 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and his wife Pfizer said in a statement.
The global test was introduced in July, aiming to add approximately 120 international sites and search for up to 30,000 participants in total.
More than 25,000 participants were registered, BioNTech said, adding that it was still on track to seek approval of BNT162b2 next month (report via Ludwig Burger; edited through Thomas Seythal).
All quotes were delayed by at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.